Dana Farber Cancer Institute Building Background

Master Class for Oncologists

Information regarding our 2022 activities
coming soon!

The Dana-Farber Cancer Institute's Master Class Virtual Series is specifically designed to assist community oncologists with self-assessing and improving their knowledge, clinical skills, and competence in the diagnosis, treatment, and overall management of a wide range of common cancers. Emphasis is placed on incorporating emerging clinical trial evidence and newer therapeutic approaches into current best practices. Master Class education takes place at a level similar to that of major national oncology sessions, but is uniquely tailored to fill identified knowledge, competence, and performance gaps among practicing community oncologists.

The virtual series consists of six live sessions beginning October 15, 2021 and wrapping up on November 6, 2021. Please visit the schedule section of the website for session agendas.

Special Features Include:

  • A notes feature will be enabled for all slides presented during each live session. Attendees have the option of making notes directly to the slides which will be emailed at the conclusion of each session. A paper syllabus will not be provided.
  • PDFs of the presentation slides will be posted to the website two days prior to the start of each session. PDFs can be downloaded and printed by attendees if needed.
  • Unable to join in for all live sessions? No problem! All sessions will be captured and placed on the website from November 19, 2021 until November 22, 2022.

Target Audience

The Master Class curriculum is intended to educate community oncologists (MDs and DOs) across the US. Master Class participation usually includes other members of the oncology care team as well, such as internal medicine physicians, advanced practice nurses, and nurse practitioners.

Dr Robert Mayer, MD
Course Director
Robert J. Mayer, MD


Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity.

  • Astellas
  • AstraZeneca Pharmaceuticals LP
  • Eisai
  • Genentech
  • Merck
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Taiho Oncology

This educational activity is supported by an educational grant from GlaxoSmithKline.


MOC Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters and Dana Farber Cancer Institute. CME Outfitters is accredited by the ACCME to provide continuing medical education for physicians.

CME Outfitters designates this activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


CME activities sponsored by CME Outfitters and Dana-Farber are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.

Course schedule

During the past 13 years, our Master Class courses have always stressed the dialogue between our faculty and our registrants with a goal of sharing new advances and practice options to enhance the care of all our patients. Our virtual agenda maintains this tradition, providing updates on advances in cancer care and maintaining the interaction between speakers and the audience that has made these sessions so special.

Robert J. Mayer, MD – Course Director


“Very well designed in an easy take-home-message format. Excellent sessions with great reviews as well as up-to-the-minute data.”

- 2020 Virtual Series Attendee

Master Class for Oncologists

Information regarding our 2022 activities coming soon!

© 2021 Dana-Farber Cancer Institute's Master Class Virtual Series. All rights reserved.